Luteolin Causes 5'CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells.
DNA methylation
antimigration
antiproliferation
histone modification
luteolin
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
06 Apr 2022
06 Apr 2022
Historique:
received:
08
03
2022
revised:
04
04
2022
accepted:
04
04
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Cancer progression is linked to abnormal epigenetic alterations such as DNA methylation and histone modifications. Since epigenetic alterations, unlike genetic changes, are heritable and reversible, they have been considered as interesting targets for cancer prevention and therapy by dietary compounds such as luteolin. In this study, epigenetic modulatory behaviour of luteolin was analysed on HeLa cells. Various assays including colony forming and migration assays, followed by biochemical assays of epigenetic enzymes including DNA methyltransferase, histone methyl transferase, histone acetyl transferase, and histone deacetylases assays were performed. Furthermore, global DNA methylation and methylation-specific PCR for examining the methylation status of CpG promoters of various tumour suppressor genes (TSGs) and the expression of these TSGs at transcript and protein level were performed. It was observed that luteolin inhibited migration and colony formation in HeLa cells. It also modulated DNA methylation at promoters of TSGs and the enzymatic activity of DNMT, HDAC, HMT, and HAT and reduced the global DNA methylation. Decrease in methylation resulted in the reactivation of silenced tumour suppressor genes including
Identifiants
pubmed: 35409426
pii: ijms23074067
doi: 10.3390/ijms23074067
pmc: PMC8999529
pii:
doi:
Substances chimiques
DNA Modification Methylases
EC 2.1.1.-
Histone Deacetylases
EC 3.5.1.98
Luteolin
KUX1ZNC9J2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Zayed University and MAHE INTERNAL RESEARC GRANT
ID : RIF grant no. R19056 AND R&DP/MUD/RL-06/2018
Références
Oncogene. 2013 Jun 6;32(23):2882-90
pubmed: 22797064
Oncotarget. 2015 Dec 22;6(41):43806-18
pubmed: 26517526
Biomolecules. 2017 Jan 05;7(1):
pubmed: 28067760
Toxicol Lett. 2015 Mar 4;233(2):214-25
pubmed: 25596314
Mol Nutr Food Res. 2011 Jan;55(1):32-45
pubmed: 21207511
Breast Cancer Res Treat. 2004 Nov;88(1):75-85
pubmed: 15538048
Exp Ther Med. 2014 Mar;7(3):560-564
pubmed: 24520245
Oncol Lett. 2016 Oct;12(4):2613-2621
pubmed: 27703524
Oncogene. 2004 Nov 25;23(55):8876-86
pubmed: 15467734
Toxicol In Vitro. 2011 Feb;25(1):213-21
pubmed: 21078381
Chin J Cancer. 2017 Jun 19;36(1):50
pubmed: 28629389
Molecules. 2015 Dec 17;20(12):22578-620
pubmed: 26694341
Cell Death Dis. 2017 Feb 9;8(2):e2612
pubmed: 28182003
Eur J Cancer Prev. 2016 Jan;25(1):65-76
pubmed: 25714651
Oncol Lett. 2017 Aug;14(2):1993-2000
pubmed: 28789432
Brief Funct Genomics. 2013 May;12(3):231-43
pubmed: 23325510
Acta Physiol (Oxf). 2011 Jun;202(2):103-18
pubmed: 21401888
Oncol Rep. 2019 Jul;42(1):131-141
pubmed: 31059061
Eur J Pharmacol. 2011 Jan 25;651(1-3):18-25
pubmed: 21074525
Epigenomics. 2011 Aug;3(4):503-18
pubmed: 22022340
Front Genet. 2022 Jan 12;12:768130
pubmed: 35096000
Pharmacol Ther. 2013 Feb;137(2):153-71
pubmed: 23041058
Curr Top Med Chem. 2016;16(7):680-96
pubmed: 26303417
Mol Med Rep. 2012 Jul;6(1):232-8
pubmed: 22552526
Oncol Lett. 2019 Apr;17(4):3842-3850
pubmed: 30930986
Viruses. 2017 Sep 01;9(9):
pubmed: 28862667
Nutrients. 2016 Sep 21;8(9):
pubmed: 27657126
J Nutr. 2010 Sep;140(9):1607-14
pubmed: 20631324
Antioxid Redox Signal. 2012 Jul 15;17(2):327-39
pubmed: 22404530
Tumour Biol. 2014 Aug;35(8):7877-85
pubmed: 24828012
J Environ Pathol Toxicol Oncol. 2014;33(3):219-31
pubmed: 25272060
J Nutrigenet Nutrigenomics. 2011;4(5):275-92
pubmed: 22353664
Curr Med Chem. 2010;17(17):1756-68
pubmed: 20345345
Oncol Rep. 2015 Apr;33(4):1976-84
pubmed: 25682960
Acta Pharmacol Sin. 2012 Oct;33(10):1325-31
pubmed: 22983392
Cancer Manag Res. 2018 Nov 22;10:6157-6166
pubmed: 30538563
Clin Epigenetics. 2015 Jul 10;7:64
pubmed: 26161152
World J Biol Chem. 2015 Nov 26;6(4):333-45
pubmed: 26629316
Biosci Rep. 2019 May 14;39(5):
pubmed: 30967496
Cancer Prev Res (Phila). 2014 Jan;7(1):65-73
pubmed: 24403290
Genes Chromosomes Cancer. 2014 May;53(5):422-31
pubmed: 24532317
Biochemistry (Mosc). 2015 Aug;80(8):972-89
pubmed: 26547065
J Nutr. 2007 Jan;137(1 Suppl):223S-228S
pubmed: 17182830
Anticancer Agents Med Chem. 2012 Dec;12(10):1159-84
pubmed: 22583402
J Pediatr Surg. 2014 Jan;49(1):159-65
pubmed: 24439602
Biomed Pharmacother. 2019 Apr;112:108612
pubmed: 30798142
Mol Cancer. 2015 Apr 12;14:83
pubmed: 25889801
Mutat Res Rev Mutat Res. 2017 Jul;773:161-173
pubmed: 28927526
PLoS One. 2016 Sep 22;11(9):e0162956
pubmed: 27658199
Biochem Pharmacol. 2010 Dec 15;80(12):1771-92
pubmed: 20599773
Annu Rev Pharmacol Toxicol. 2008;48:257-76
pubmed: 17883328
Curr Pharmacol Rep. 2015 Aug;1(4):245-257
pubmed: 26328267
Phytother Res. 2021 Jul;35(7):3509-3532
pubmed: 33580629
Front Oncol. 2015 Dec 21;5:278
pubmed: 26734566
Nutr Cancer. 2018 May-Jun;70(4):594-604
pubmed: 29693446
Mol Pharmacol. 2005 Oct;68(4):1018-30
pubmed: 16037419
Oncol Rep. 2014 Jun;31(6):2683-91
pubmed: 24789165
Med Res Rev. 2016 Nov;36(6):1036-1079
pubmed: 27406026
Clin Epigenetics. 2012 Mar 12;4(1):5
pubmed: 22414492
Biol Cell. 2006 Mar;98(3):141-52
pubmed: 16480340
Oncogene. 2002 Aug 12;21(35):5427-40
pubmed: 12154405
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Int J Mol Sci. 2019 Jun 27;20(13):
pubmed: 31252615
Antioxidants (Basel). 2019 Nov 15;8(11):
pubmed: 31731716
Biosci Rep. 2019 Aug 13;39(8):
pubmed: 31366565
EMBO J. 1999 Sep 1;18(17):4779-93
pubmed: 10469656
Public Health Genomics. 2017;20(2):100-115
pubmed: 28521327
Cancers (Basel). 2020 Jun 08;12(6):
pubmed: 32521759
Food Funct. 2019 Feb 20;10(2):703-712
pubmed: 30663726
Cold Spring Harb Protoc. 2016 Aug 01;2016(8):
pubmed: 27480717
Transl Cancer Res. 2019 Jun;8(3):950-961
pubmed: 35116834
Oncotarget. 2016 Aug 2;7(31):50719-50734
pubmed: 27191891
Chem Biol Interact. 2002 Jan 22;139(1):1-21
pubmed: 11803026
PLoS One. 2015 Mar 31;10(3):e0122495
pubmed: 25826459